Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.7 | 2.2 |
NAV | ₹20.66 | ₹100.82 |
Fund Started | 20 Nov 2020 | 25 Mar 1997 |
Fund Size | ₹910.36 Cr | ₹1072.74 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 22.84% | 26.58% |
3 Year | 15.99% | 25.59% |
5 Year | - | 24.49% |
1 Year
3 Year
5 Year
Equity | 69.58% | 99.31% |
Cash | 30.42% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 5.86% |
ITC Ltd. | 3.80% |
Berkshire Hathway Inc (US) | 3.43% |
Larsen & Toubro Ltd. | 3.19% |
Infosys Ltd. | 2.94% |
Power Grid Corporation Of India Ltd. | 2.51% |
Cipla Ltd. | 2.40% |
HCL Technologies Ltd. | 1.99% |
Sun Pharmaceutical Industries Ltd. | 1.88% |
GAIL (India) Ltd. | 1.85% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Jay Kothari | Satish Ramanathan |
Start Date | 16 Mar 2018 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to generate consistent returns by investing in equity and equity related or fixed income securities which are currently undervalued. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 20 Nov 2020 | 25 Mar 1997 |
Description
Launch Date